Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. 1 Persistent infection with a high-risk strain can lead to serious health problems including cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers as well as genital warts in both men and women. 2 Currently, there are 3 US Food and Drug Administrationapproved HPV vaccines, for which multiple doses are recommended. 3 -5 The Centers for Disease Control and Prevention has recommended routine HPV vaccination for girls ages 11 to 12 since 2006 and for boys ages 11 to 12 since 2009, with catch-up vaccination for older adolescents and young adults. 6, 7 However, despite the availability of the vaccines, uptake remains low, with only 49.5% of girls and 37.5% of boys having up-to-date HPV vaccinations in 2016. 8 Many reasons for the low uptake of the HPV vaccine have been proposed, including high costs and poor access, difficulty completing the multidose regimen, safety and health concerns, and worries that the vaccine will promote unsafe sexual activity among adolescents. 9 -12 Currently, 23 states and the District of Columbia have successfully passed legislation regarding HPV to help improve HPV vaccination coverage. 13 These policies vary in terms of leniency and include requiring schools to provide information about HPV vaccination to students, subsidizing costs and incentivizing insurers to cover the vaccine, and mandating vaccination (Supplemental Table 4 ). 13 Further adoption of these policies has been hampered by a number of concerns. 13, 14 One concern is that encouraging adoption of the HPV vaccination may encourage risky sexual behaviors among adolescents, and it may be seen as conflicting with abstinence only sexual education. 14 -17 Consequently, many states have had to defer vaccination mandates and instead pass related legislation focusing on HPV education or cost. 17, 18 Although in recent research no changes in sexually transmitted infections among privately insured individuals receiving the HPV vaccine have been found, the broader impacts of policies to increase vaccine uptake on sexual behaviors in the general adolescent population have not been examined. 19 Rigorous evidence in this domain will be critical as policymakers continue to grapple with strategies to raise vaccination rates.
In this study, we examined the impact of state-level legislation aiming to raise awareness and uptake of HPV vaccination on adolescent sexual behaviors. We used a quasiexperimental difference-in-difference approach to assess how the policy is associated with the number of sexual partners and condom use during last sexual intercourse. 20 
METHODS
Data on the outcomes of adolescent sexual behaviors were collected from the 2001 to 2015 state Youth Risk Behavior Surveillance System (YRBSS). 21 The state YRBSS is a large, state-representative, biannual, school-based survey of ninth-to 12th-grade students from the United States. Underrepresented minorities were purposely oversampled at each stage of the 3-stage sampling procedure. 22 The state YRBSS survey collected information from students in 25 states without HPV legislation and 16 states with HPV legislation (Supplemental Table 4 ). States could choose when they wanted to publicly report their results, so the coverage of states differed each year during our study period.
The YRBSS asked students to report if they ever had sexual intercourse in the last 3 months and if they used a condom the last time they had sexual intercourse. Ever having sexual intercourse during the last 3 months was a binary yes or no variable (0 for people who never had sex or did not have sex in the last 3 months, 1 for people who had sex during the last 3 months). Condom use during last sexual intercourse was a binary yes or no variable that was conditional on ever having had sex in the last 3 months. As a secondary outcome, we looked at the number of sexual partners during the last 3 months as a continuous variable from 0 (people who never had sex or did not have sex in last 3 months) to 6 (6 or more partners in the last 3 months).
The main exposure was whether respondents' state of residence had legislation aiming to raise HPV vaccination rates in place during the year of the interview. Information on the type of policy and year of passage was obtained from the National Conference of State Legislatures (Supplemental Table 4 ). 13 The exposure was then further categorized by the type of legislation that was passed: vaccination mandates, HPV education (in schools, for parents, general awareness, research funds), and vaccine cost and accessibility (cost of vaccine, insurance coverage, prescription requirements).
We used difference-in-difference models to study the association of the legislation with adolescent sexual behaviors. 20 We compared changes in sexual behavior for adolescents living in states that passed HPV legislation before and after policy implementation against the same changes in states that did not pass legislation. In our model, we adjusted for respondent age, sex, race, and grade. To adjust for potential confounders for the association between the states with legislation and adolescent sexual health behaviors, we added state-year factors to the model, including state-specific linear time trends. In our models, we include state effects that account for any fixed differences between states (such as political, educational, or teen-aged pregnancy differences) and also include year effects that account for any trends in the risky teenager sexual behaviors over time that are similar across all states. As a secondary analysis, we also adjusted for rates of unemployment, teen-aged pregnancies, and sexually transmitted diseases among teenagers ages 15 to 19 as well as the Children's Health Insurance Program (CHIP) and the Medicaid program of the states, the majority political party of the state legislature, and the political party of the governor. CHIP and Medicaid were included in case any changes to health care coverage for adolescents or vaccinations occurred around the same time that legislation was passed and could be acting as a confounder for the relationship between legislation and adolescent sexual behaviors. We estimated models, defining the exposure as passage of any policy as well as passage of specific types of legislation, including mandates, legislation about vaccine cost or access, and legislation about education. Because of the small number of states with mandates and the timing of the mandates, we were not able to examine the effect of the mandates separately and instead, they are only included in the any policy analysis.
Although our main outcomes were binary variables, we used ordinary least squares regression to estimate our models. This is because there are well-known biases in limited dependent variable estimators in fixed effect models. 23 For all models, we corrected SEs for clustering at the state level to account for serial correlation in the outcome. 24 Survey weights were used when examining the descriptive characteristics of states with legislation compared with states without legislation. Survey weights were not used in the difference-in-difference models because individual-level error terms clustered within a larger group (each state) could yield inappropriately inflated SEs. 25 Additionally, we did not a priori expect large heterogeneous effects because the survey was not sampled by the outcome of interest. 25 However, we still ran the main models using the survey weights to compare with our main models that did not include survey weights.
We estimated several additional models. First, we assessed potential violations of the parallel trends assumption of the difference-indifference model. 20 Specifically, we examined whether trends in sexual behavior before policy implementation differed in states passing policies versus those that did not. Second, we estimated our main models by subgroups of age, sex, grade, and race and/or ethnicity. Bonferroni corrections were used to account for multiple testing. With 18 main regressions run for the analysis, results were considered statistically significant when the P value was <.003. Third, because an assumption of this model is that the effects are immediate, we did a lagged analysis to see what happened when we looked at the effect of the legislation among students years after it was passed. The idea of the lag is that most HPV vaccination education and coverage should be affecting 11-to 12-year-olds, and our YRBSS data are taken from older students (mainly 15-18-year-olds), so looking at a lagged timing of legislation will let us see if the effect of the legislation was limited to kids who were age 11 to 12 at the time of the legislation. Additionally, in the lagged analysis, we also account for the fact that implementation of the legislation most often happened the year after the policy was passed. However, because states did not always report their data for every survey year, we do not have as many states reporting their data after 2011, and lagged results should be interpreted with caution. Fourth, as a prespecified falsification test, we also examined lead effects because the first HPV vaccine was approved in 2006. 26 This study is exempt from human subjects review by the institutional review board given the use of publicly available, deidentified data. In additional analyses, we did not find evidence that the parallel trends assumption was violated (Supplemental Table 5 ). Subgroup analyses revealed some difference by age, sex, and ethnicity, but no group showed statistically significant increases in any sexual behaviors after the policy. It appeared that girls had larger decreases in recent sexual intercourse and had larger increases in condom use than boys. Students under age 17 had larger decreases in recent sexual intercourse and larger increases in condom use than students ages 17 or 18. There were no differences seen by race and/or ethnicity for the number of sexual partners. White students saw a smaller percentage point increase in condom use than African American, Hispanic, and other race and/or ethnicity students. There was no difference when CHIP, Medicaid, political party, unemployment, teen-aged pregnancy rates, and sexually transmitted disease rates were included in the models (Supplemental Table 6 ). Analyses in which we examined lagged impacts suggested a substantive, but not statistically significant, 6.1% point decrease (P = .009) in recent sexual intercourse and a 5.9% point increase (P = .046) in condom use (prespecified P value threshold of P < .003) (Supplemental Table 7 ). Results did not differ for the secondary outcome examined of number of sexual partners during the last 3 months. For the secondary outcome of number of sexual partners in the last 3 months, there was a nonsignificant decrease in the number of sexual partners by 0.02 (P = .18) in states that enacted HPV legislation compared with states that did not enact HPV legislation (Table 3) . Lastly, as expected, the estimates from models in which we included the YRBSS sample weights were less precisely estimated, but the interpretation of the main effects was similar (Supplemental Table 8 ).
RESULTS

DISCUSSION
In this national study, we found no association between the passage of legislation designed to increase uptake of the HPV vaccine and sexual behaviors among high school-going adolescents in the United States. This finding was consistent across subgroups and robust to different specifications and sensitivity tests.
Despite long-standing knowledge of the protective benefits of the HPV vaccine, vaccination rates in the United States remain low. 27 Even among those receiving the vaccine, the timing of HPV vaccination often occurs after sexual debut and HPV exposure, reducing its potential efficacy. A study conducted in the NHANES found that 43% of girls with at least 1 dose of the HPV vaccine had sex before or during the same year as their first HPV vaccination. 28 Ensuring that adolescents receive the HPV vaccination before their first sexual experience is important to helping prevent the negative health effects of HPV infections. Policies to educate adolescents and their families about the benefits of vaccination and increase access will likely be an important part of the policy response to improve vaccination rates.
Thus far, researchers have found minimal, if any, benefits of these policies on vaccination rates. 29 -32 In states that have implemented these policies, the ultimate legislation passed was often less expansive than other debated options. The lessexpansive options passed included additions such as opt-out options for vaccine mandates that may have reduced the number of adolescents vaccinated and weakening of the policy to just be educational. 29 The weakening of the legislation was in part due to concerns about behavioral responses to the policy in addition to a number of other concerns around ethics, health benefits, and side effects. 14 -16 In our study, we show that the policy options implemented thus far have not raised the risk of risky sexual activity. Additionally, adolescents appear to be engaged in less sexual intercourse over time, even with increasing availability of HPV vaccination. 
FIGURE 1
Adolescent sexual behaviors over time in states with HPV legislation and states without HPV legislation. A, Sexual intercourse during the last 3 months. B, Condom use during last sexual intercourse. In A, we show the percentage of adolescents ever having sexual intercourse over the last 3 months for states that passed HPV legislation (solid black line) and states that did not pass HPV legislation (dashed black line). In B, we show the percentage of adolescents using condoms the last time they had sexual intercourse for states that passed HPV legislation (solid black line) and states that did not pass HPV legislation (dashed black line). Most states that passed HPV legislation did so in 2007. The first HPV vaccination was approved by the US Food and Drug Administration in 2006.
States, can be used to provide support for the reintroduction and strengthening of legislation regarding the HPV vaccine. Concern that legislation will increase risky adolescent sexual behaviors should not be used when deciding to pass legislation regarding HPV vaccination. 
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